High-resolution crystal structure reveals molecular details of target recognition by bacitracin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 35, 2013, Pages 14207-14212

  Economou, Nicoleta J ^a,b   Cocklin, Simon ^a   Loll, Patrick J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b University of North Carolina   (United States)

Author keywords

Antibiotic resistance; Molecular recognition; X ray crystallography

Indexed keywords

BACITRACIN; BACITRACIN A; GRAMICIDIN S; LIPID; PYROPHOSPHORIC ACID DERIVATIVE; SODIUM ION; UNCLASSIFIED DRUG; ZINC;

ARTICLE; BACTERIAL MEMBRANE; CHEMICAL PARAMETERS; CHEMICAL STRUCTURE; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MIXTURE; DRUG STRUCTURE; DRUG TARGETING; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL;

ANTIBIOTIC RESISTANCE; MOLECULAR RECOGNITION; X-RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; BACITRACIN; CELL MEMBRANE; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYISOPRENYL PHOSPHATES; PROTEIN BINDING; PROTEIN CONFORMATION; SURFACE PLASMON RESONANCE;

EID: 84883392796     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1308268110     Document Type: Article

References (44)

1. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science 325(5944): 1089-1093.
2. Appelbaum PC (2012) 2012 and beyond: Potential for the start of a second pre-antibiotic era? J Antimicrob Chemother 67(9):2062-2068.
3. Wright GD (2011) Molecular mechanisms of antibiotic resistance. Chem Commun (Camb) 47(14):4055-4061.
4. Johnson BA, Anker H, Meleney FL (1945) Bacitracin: A new antibiotic produced by a member of the B. subtilis group. Science 102(2650):376-377.
5. Meleney FL, Johnson B (1947) Bacitracin therapy; the first hundred cases of surgical infections treated locally with the antibiotic. J Am Med Assoc 133(10):675-680.
6. Ming LJ, Epperson JD (2002) Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin. J Inorg Biochem 91(1):46-58.
7. Konz D, Klens A, Schörgendorfer K, Marahiel MA (1997) The bacitracin biosynthesis operon of Bacillus licheniformis ATCC 10716: Molecular characterization of three multi-modular peptide synthetases. Chem Biol 4(12):927-937.
8. Nakano MM, Zuber P (1990) Molecular biology of antibiotic production in Bacillus. Crit Rev Biotechnol 10(3):223-240.
9. Rieder H, Heinrich G, Breuker E, Simlot MM, Pfaender P (1975) Bacitracin synthetase. Methods Enzymol 43:548-559.
10. Kopp F, Marahiel MA (2007) Macrocyclization strategies in polyketide and nonribosomal peptide biosynthesis. Nat Prod Rep 24(4):735-749.
11. Ikai Y, et al. (1995) Total structures and antimicrobial activity of bacitracin minor components. J Antibiot (Tokyo) 48(3):233-242.
12. Tsuji K, Robertson JH (1975) Improved high-performance liquid chromatographic method for polypeptide antibiotics and its application to study the effects of treatments to reduce microbial levels in bacitracin powder. J Chromatogr A 112:663-672.
13. Davies J, Ryan KS (2012) Introducing the parvome: Bioactive compounds in the microbial world. ACS Chem Biol 7(2):252-259.
14. Tay WM, Epperson JD, da Silva GF, Ming LJ (2010) 1H NMR, mechanism, and mononuclear oxidative activity of the antibiotic metallopeptide bacitracin: The role of D-Glu-4, interaction with pyrophosphate moiety, DNA binding and cleavage, and bioactivity. J Am Chem Soc 132(16):5652-5661.
15. Stepanov VM, Rudenskaya GN, Gaida AV, Osterman AL (1981) Affinity chromatography of proteolytic enzymes on silica-based biospecific sorbents. J Biochem Biophys Methods 5(3):177-186.
16. Dickerhof N, Kleffmann T, Jack R, McCormick S (2011) Bacitracin inhibits the reductive activity of protein disulfide isomerase by disulfide bond formation with free cysteines in the substrate-binding domain. FEBS J 278(12):2034-2043.
17. Karala AR, Ruddock LW (2010) Bacitracin is not a specific inhibitor of protein disulfide isomerase. FEBS J 277(11):2454-2462.
18. Storm DR, Strominger JL (1973) Complex formation between bacitracin peptides and isoprenyl pyrophosphates. The specificity of lipid-peptide interactions. J Biol Chem 248(11):3940-3945.
19. Storm DR (1974) Mechanism of bacitracin action: A specific lipid-peptide interaction. Ann N Y Acad Sci 235(0):387-398.
20. Toscano WA, Jr., Storm DR (1982) Bacitracin. Pharmacol Ther 16(2):199-210.
21. Stone KJ, Strominger JL (1971) Mechanism of action of bacitracin: complexation with metal ion and C 55 -isoprenyl pyrophosphate. Proc Natl Acad Sci USA 68(12): 3223-3227.
22. Kobayashi N, Takenouchi T, Endo S, Munekata E (1992) 1H NMR study on the conformation of bacitracin A in aqueous solution. FEBS Lett 305(2):105-109.
23. Pons M, Feliz M, Antònia Molins M, Giralt E (1991) Conformational analysis of bacitracin A, a naturally occurring lariat. Biopolymers 31(6):605-612.
24. Pfeffer S, Höhne W, Branner S, Wilson K, Betzel C (1991) X-Ray structure of the antibiotic bacitracin A. FEBS Lett 285(1):115-119.
25. Pfeffer-Hennig S, et al. (1996) Three dimensional structure of the antibiotic bacitracin A complexed to two different subtilisin proteases: Novel mode of enzyme inhibition. Adv Exp Med Biol 379:29-41.
26. Epperson JD, Ming LJ (2000) Proton NMR studies of Co(II) complexes of the peptide antibiotic bacitracin and analogues: Insight into structure-activity relationship. Biochemistry 39(14):4037-4045.
27. Drabløs F, Nicholson DG, Rønning M (1999) EXAFS study of zinc coordination in bacitracin A. Biochim Biophys Acta 1431(2):433-442.
28. Harding MM (1999) The geometry of metal-ligand interactions relevant to proteins. Acta Crystallogr D Biol Crystallogr 55(Pt 8):1432-1443.
29. Scogin DA, Baldwin TO, Gennis RB (1983) Studies on the complex formed between bacitracin A and divalent cations. Biochim Biophys Acta 742(1):184-188.
30. Page MJ, Di Cera E (2006) Role of Na+ and K+ in enzyme function. Physiol Rev 86(4): 1049-1092.
31. Bauer R, Dicks LM (2005) Mode of action of lipid II-targeting lantibiotics. Int J Food Microbiol 101(2):201-216.
32. Hsu ST, et al. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11(10):963-967.
33. Müller A, Ulm H, Reder-Christ K, Sahl HG, Schneider T (2012) Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors. Microb Drug Resist 18(3):261-270.
34. MacDonald RI, MacDonald RC, Cornell NW (1974) Perturbation of liposomal and planar lipid bilayer membranes by bacitracin-cation complex. Biochemistry 13(19): 4018-4024.
35. Qi ZD, et al. (2008) Characterization of the mechanism of the Staphylococcus aureus cell envelope by bacitracin and bacitracin-metal ions. J Membr Biol 225(1-3):27-37.
36. Sleytr UB, Oliver TC, Thorne KJ (1976) Bacitracin-induced changes in bacterial plasma membrane structure. Biochim Biophys Acta 419(3):570-573.
37. Bridgewater JD, Lim J, Vachet RW (2006) Transition metal-peptide binding studied by metal-catalyzed oxidation reactions and mass spectrometry. Anal Chem 78(7): 2432-2438.
38. Mosberg HI, Scogin DA, Storm DR, Gennis RB (1980) Proton nuclear magnetic resonance studies on bacitracin A and its interaction with zinc ion. Biochemistry 19(14): 3353-3357.
39. Scogin DA, Mosberg HI, Storm DR, Gennis RB (1980) Binding of nickel and zinc ions to bacitracin A. Biochemistry 19(14):3348-3352.
40. Bonev BB, Breukink E, Swiezewska E, De Kruijff B, Watts A (2004) Targeting extracellular pyrophosphates underpins the high selectivity of nisin. FASEB J 18(15): 1862-1869.
41. Pavli V, Kmetec V (2001) Optimization of HPLC method for stability testing of bacitracin. J Pharm Biomed Anal 24(5-6):977-982.
42. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66(pt 2):213-221.
43. Oman TJ, van der Donk WA (2009) Insights into the mode of action of the twopeptide lantibiotic haloduracin. ACS Chem Biol 4(10):865-874.
44. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(suppl 1):5-16.